GLP-1 Drugs Linked to GI Effects, Uncertain Signals - Summary - MDSpire
From the Journals

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.

Share

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were analyzed across 60 meta-analyses involving 1,751 trials with 3.6 million participants, predominantly those with type 2 diabetes or obesity. Strong associations were noted for gastrointestinal issues such as nausea, vomiting, and diarrhea, with evidence quality rated from high to moderate. Serological links to lower risks of serious infections and respiratory diseases were indicated, though many findings lacked strong corroborative evidence. Lead author Kaijie Yang, MD, underscores the insufficiency of high-certainty conclusions from the current body of research.

Original Source(s)

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

  • by Kathryn Wighton

  • April 16, 2026

Related Content

BMI-Adjusted Grip Strength and Sarcopenia in Prediabetes

Researchers report 8% prevalence of probable sarcopenia and a 96.4% specificity cutoff for BMI-adjusted grip strength.

Digital Twins for Rare Diseases

AI-driven models address data gaps in rare disease research and diagnostics

  • April 20, 2026

  • 5 min
The Top 40 Under 40 Power List 2026: Nominations Are Open! 

Nominate a rising star in analytical science 

  • April 17, 2026

  • 1 min